Clinical aspects of parvovirus B19 infection

Authors

  • K. BROLIDEN,

    1. From the Department of Medicine, Solna, Unit of Infectious Diseases, Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Search for more papers by this author
  • T. TOLFVENSTAM,

    1. From the Department of Medicine, Solna, Unit of Infectious Diseases, Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Search for more papers by this author
  • O. NORBECK

    1. From the Department of Medicine, Solna, Unit of Infectious Diseases, Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Search for more papers by this author

Prof. Kristina Broliden, Department of Medicine, Solna, Unit of Infectious Diseases, B2:00, Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Solna, 171 76 Stockholm, Sweden.
(fax: +46 8 7178501; e-mail: kristina.broliden@karolinska.se).

Abstract.

Parvovirus B19 is a significant human pathogen that causes a wide spectrum of clinical complications ranging from mild, self-limiting erythema infectiosum in immunocompetent children to lethal cytopenias in immunocompromised patients and intrauterine foetal death in primary infected pregnant women. The infection may also be persistent and can mimic or trigger autoimmune inflammatory disorders. Another important clinical aspect to consider is the risk of infection through B19-contaminated blood products. Recent advances in diagnosis and pathogenesis, new insights in the cellular immune response and newly discovered genotypes of human parvoviruses form a platform for the development of modern therapeutic and prophylactic alternatives.

Ancillary